Synopsis: Read together, the announcements point to a single underlying thesis: both companies are at genuine revenue inflection points and are using richly valued equity at 97x and 71x trailing PE respectively to pre-fund the physical and operational capacity that the next phase of their growth will require.
Gujarat Themis Biosyn, Vapi’s niche anti-TB API maker, approved raising Rs. 1,000 crore via QIP and preferential issue at a June 6 board meeting that ran two hours. ASM Technologies, the Bengaluru engineering services firm with delivery centres across six countries, approved raising Rs. 500 crore through a similarly open-ended instrument menu at a board meeting the same morning. Neither company disclosed a use of proceeds. Both are profitable. Neither needs the capital to survive. What they need it for and what connects them is the infrastructure to sustain a revenue step-change that is already underway.
With a market capitalization range of Rs. 4,500-4,600 crore, the shares of ASM Technologies Ltd and Gujarat Themis Biosyn Ltd were last recorded at Rs. 3,149.95 and Rs.417 per share. The shares have given 1 year return of 41.99 percent and 20.24 percent respectively.
The One Underlying Use
At Gujarat Themis Biosyn, quarterly depreciation has risen from Rs. 1 crore in mid-2024 to Rs. 4 crore by December 2025 a fourfold increase that reflects substantial fixed asset investment already in progress, almost certainly on fermentation capacity. Fermentation-based API manufacturing is capital-intensive.
The company’s current annual revenue of approximately Rs. 160–170 crore is built almost entirely on Rifampicin, a first-line anti-tuberculosis drug. A Rs. 1,000 crore raise six times that revenue makes sense only if the company is building out capacity for additional molecules, executing a large-scale Rifampicin capacity expansion to capture global TB programme demand, or both. The scale of the raise, relative to the existing business, is not an incremental step. It is a structural transformation.
At ASM Technologies, the signal is in the revenue line itself. Quarterly revenues of Rs. 44–57 crore through FY23 and early FY24 gave way to Rs. 114 crore in the March 2025 quarter, Rs. 122 crore in June 2025, and Rs. 154 crore in September 2025 a near-tripling in three quarters without a disclosed acquisition.
For an engineering services company, revenue of this magnitude at this pace typically means a handful of very large, multi-year contracts have been signed with global OEM or technology clients. Executing those contracts at quality requires delivery infrastructure: offshore development centres, equipment, expanded workforce, and in some cases co-located labs or hardware testing facilities.
Gujarat Themis Biosyn’s QIP is the bolder of the two in relative terms. A Rs. 1,000 crore raise against Rs. 160 crore in annual revenue, if fully equity-funded at current market price, implies issuing approximately 3.5 crore new shares against a base of 10.9 crore roughly 32 percent dilution. The operational quality is not in dispute: 17.4 percent ROCE, a 40–49 percent OPM range, and an almost debt-free balance sheet establish that Themis runs its existing business extremely well.
The question investors will ask at the EGM is whether a company that has compounded this carefully should be issuing 32 percent equity dilution without a detailed capex roadmap.
ASM Technologies’ Rs. 500 crore raise is proportionally more contained approximately 11 percent dilution at current market price against a Rs. 4,594.72 crore market cap. The more pressing concern for ASM investors is not the raise itself but the sustainability of the revenue inflection. A 89 percent profit CAGR over five years and the recent quarterly revenue surge are impressive, but debtors at 80 days on a rapidly growing book and a three-year ROE of only 17 percent suggest that returns on incremental capital have been very good. The QIP capital needs to be deployed at returns that improve, rather than maintain, that ROE trajectory.
Business Overview
Gujarat Themis Biosyn Limited, incorporated in 1981 and managed by Themis Medicare Ltd, manufactures Rifampicin and other APIs through fermentation at its Vapi, Gujarat facility. FY26 revenue is approximately Rs. 166 crore with OPM in the 46 percent range.
ASM Technologies Limited, incorporated and headquartered in Bengaluru, provides engineering consulting and product R&D services with global presence across the USA, UK, Singapore, Canada, Mexico, and Japan. FY26 consolidated revenue is approximately Rs. 529 crore with net profit of approximately Rs. 61 crore.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
